Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 5/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669418 | 0.86 | TTBK1 (0.40) | AHRDRD2HTR1APARP1KDM4E | |
| SCHEMBL1536537 | 0.77 | PARP1 (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL4898754 | 0.77 | DRD2 (0.32) | AHRDRD2HTR1APARP1DRD4 | |
| SCHEMBL1978270 | 0.76 | MEN1 (0.41) | ADRA2AADRA2CAHRHTR1ACREBBP | |
| SCHEMBL11437391 | 0.75 | AHR (0.39) | AHRDRD2PARP1ADRB1DRD4 | |
| SCHEMBL3249002 | 0.75 | CYP1A2 (0.42) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL6092206 | 0.73 | HTR1D (0.47) | ADRA2AADRA2CDRD2HTR1A | |
| SCHEMBL29952248 | 0.73 | DRD2 (0.40) | AHRDRD2HTR1APARP1SLC6A4 | |
| SCHEMBL5954699 | 0.71 | AHR (0.35) | AHRDRD2PARP1DRD4DRD3 | |
| SCHEMBL4537537 | 0.70 | ADRA2A (0.40) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105199709-A | Electrochromic material and preparation method thereof | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-12-30 | — | — | CN | claimed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| CN-105199709-B | A kind of electrochromic material and preparation method thereof | 青岛科技大学 | 2017-03-29 | — | — | CN | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| CN-105199709-A | Electrochromic material and preparation method thereof | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-12-30 | — | — | CN | disclosed |
| US-6593350-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-07-15 | — | — | US | disclosed |
| US-6593350-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-07-15 | — | — | US | disclosed |
| US-20030087842-A1 | Indolocarbazole anticancer agents and methods of using them | ADVANCED LIFE SCIENCES, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002088146-A3 | ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE | WYETH CORP (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020183352-A1 | Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020183352-A1 | Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002088145-A1 | AZABICYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZACYCLOPENTA[a]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088146-A2 | ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088146-A2 | ANTIDEPRESSANT INDOLETETRAHYDROPYRIDINE DERIVATIVES OF 2,3-DIHYDRO-7H-[1,4]DIOXINO[2,3-e]INDOLE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002048166-A1 | INDOLOCARBAZOLE ANTICANCER AGENTS AND METHODS OF USING THEM | ADVANCED LIFE SCIENCES, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087842-A1 | Indolocarbazole anticancer agents and methods of using them | TOP1, TOP2A, TOP2B | ADRA2A 4233/4885ADRA2C 3299/4885ADRA1D 4249/4885 |
| US-20020183352-A1 | Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole | TPH1, OPRD1, HTR1D | ADRA2A 115/4885ADRA2C 58/4885ADRA1D 21/4885 |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | CHRNA7, CHRNA2, CHRNA5 | ADRA2A 52/4885ADRA2C 32/4885ADRA1D 73/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | ADRA2A 57/4885ADRA2C 33/4885ADRA1D 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.